October 27, 2025

Reimagining Antibody Drug Discovery with AI

By focusing on functional activity, Abalone Bio is advancing CB2-targeting antibodies with the potential to transform treatment for fibrosis, neuropathy, and beyond.

The Medicine Maker

October 22, 2025

Consensus Defines Postpartum Psychosis as Distinct Clinical Entity

An international panel of leading experts on women’s mental health is recommending that postpartum psychosis be recognized as a distinct category of mental illness and classified accordingly within standardized medical coding systems.

Mount Sinai New York

October 22, 2025

Diabetic Macular Edema and the VERONA Trial

Next-generation therapy aims to cut injection frequency while maintaining vision in diabetic macular edema

The Ophthalmologist

October 21, 2025

This Week’s Biopharma News: Collaborating for Pandemic Preparedness

Our latest news roundup reports on FDA approval for oral semaglutide, suspension of a Pfizer medicine in Europe, a mAb for preventing malaria, and more

The Medicine Maker

October 21, 2025

UCI Health takes national lead in combating diabetes epidemic

With diabetes rates soaring, UCI Health launches a bold initiative to improve care, reduce disparities, and protect vulnerable communities.

UCI Health

October 14, 2025

Breast Screening: The Age Question

Screening every two years offers greater life-year gains in breast cancer care.

Conexiant

October 09, 2025

Pituitary Apoplexy: Lessons from Two Complex Cases

Pituitary apoplexy can represent a challenging diagnostic and management dilemma. Yet its serious nature demands immediate recognition, careful assessment and treatment by a multidisciplinary team. 

Baptist Health South Florida

October 07, 2025

UCI Health launches first U.S. trial of nerve-blocking device for drug-resistant hypertension

A new clinical trial at UCI Health tests a novel device that could help millions with uncontrolled high blood pressure reduce or eliminate medications.

UCI Health

October 03, 2025

Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease

The FDA approved the estrogen receptor antagonist for adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic disease with progression aft...

The ASCO Post